Polymorphisms in the promoter of the human APP gene: Functional evaluation and allele frequencies in Alzheimer disease

Archives of Neurology

Volumn 59, Issue 11, 2002, Pages 1793-1799

  Athan, Eleni S ^a,b,c,d,e   Lee, Joseph H ^a,b,c,d,e   Arriaga, Alex ^a,b,c,d,e   Mayeux, Richard P ^a,b,c,d,e   Tycko, Benjamin ^a,b,c,d,e  

^a NewYork Presbyterian Hospital   (United States)

^b Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^c Departments of Neurology Medicine   (United States)

^d Department of Pathology ^*  (United States)

^e Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; PRIORITY JOURNAL; PROMOTER REGION;

AGED; ALLELES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BASE SEQUENCE; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; FEMALE; GENE FREQUENCY; HUMANS; LOGISTIC MODELS; MALE; MICE; MOLECULAR SEQUENCE DATA; ODDS RATIO; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); SEQUENCE ALIGNMENT; TUMOR CELLS, CULTURED;

EID: 0036845563     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.59.11.1793     Document Type: Article

References (56)

1. Selkoe DJ. Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98:11039-11041.
2. Ashall F, Goate AM. Role of the beta-amyloid precursor protein in Alzheimer's disease. Trends Biochem Sci. 1994;19:42-46.
3. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron. 1996;17:1005-1013.
4. St George-Hyslop PH. Genetic factors in the genesis of Alzheimer's disease. Ann NY Acad Sci. 2000;924:1-7.
5. Roses AD. Apolipoprotein E, a gene with complex biological interactions in the aging brain. Neurobiol Dis. 1997;4:170-185.
6. Gandy S, Petanceska S. Regulation of Alzheimer β-amyloid precursor trafficking and metabolism. Biochim Biophys Acta. 2000;1502:44-52.
7. Gentleman SM, Nash MJ, Sweeting CJ, et al. Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury. Neurosci Lett, 1993;160:139-144.
8. Malherbe P, Richards JG, Martin JR, et al. Lack of β -amyloidosis in transgenic mice expressing low levels of familial Alzheimer's disease missense mutations. Neurobiol Aging. 1996;17:205-214.
9. van Leuven F. Single and multiple transgenic mice as models for Alzheimer's disease. Prog Neurobiol. 2000;61:305-312.
10. Schupf N, Patel B, Silverman W, et al. Elevated plasma amyloid β-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett. 2001;301:199-203.
11. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 1985;17:278-282.
12. Kida E, Choi-Miura NH, Wisniewski KE. Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer's disease and Down's syndrome brain. Brain Res. 1995;685:211-216.
13. Hyman BT. Down syndrome and Alzheimer disease. Prog Clin Biol Res. 1992;379:123-142.
14. Zigman WB, Schupf N, Sersen E, Silverman W. Prevalence of dementia in adults with and without Down syndrome. Am J Ment Retard. 1996;100:403-412.
15. Goldgaber D, Harris HW, Hla T, et al. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA. 1989;86:7606-7610.
16. Lahiri DK, Robakis NK. The promoter activity of the gene encoding Alzheimer beta-amyloid precursor protein (APP) is regulated by two blocks of upstream sequences. Brain Res Mol Brain Res. 1991;9:253-257.
17. Izumi R, Yamada T, Yoshikai S, et al. Positive and negative regulatory elements for the expression of the Alzheimer's disease amyloid precursor-encoding gene in mouse. Gene. 1992;112:189-195.
18. Quitschke WW, Goldgaber D. The amyloid beta-protein precursor promoter: A region essential for transcriptional activity contains a nuclear factor binding domain. J Biol Chem. 1992;267:17362-17368.
19. Quitschke WW. Two nuclear factor binding domains activate expression from the human amyloid beta-protein precursor promoter. J Biol Chem. 1994;269:21229-21233.
20. Trejo J, Massamiri T, Deng T, et al. A direct role for protein kinase C and the transcription factor Jun/AP-1 in the regulation of the Alzheimer's beta-amyloid precursor protein gene. J Biol Chem. 1994;269:21682-21690.
21. Dewji NN, Do C, Bayney RM. Transcriptional activation of Alzheimer's β-amylold precursor protein gene by stress. Brain Res Mol Brain Res. 1995;33:245-253.
22. , Lahiri DK, Nall C. Promoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1. Brain Res Mol Brain Res. 1995;32:233-240.
23. Bourbonniere M, Nalbantoglu J. The helix-loop-helix transcription factor USF interacts with the basal promoter of human amyloid precursor protein. Brain Res Mol Brain Res. 1996;35:304-308.
24. Ringheim GE, Szczepanik AM, Petko W, et al. Enhancement of beta-amyloid precursor protein transcription and expression by the soluble intedeukin-6 receptor/interleukin-6 complex. Brain Res Mol Brain Res. 1998;55:35-44.
25. Lahiri DK, Nall C, Ge YW. Promoter activity of the beta-amyloid precursor protein gene is negatively modulated by an upstream regulatory element. Brain Res Mol Brain Res. 1999;71:32-41.
26. Ruiz-Leon Y, Pascual A. Brain-derived neurotrophic factor stimulates β-amyloid gene promoter activity by a Ras-dependent/AP-1 -independent mechanism in SH-SY5Y neuroblastoma cells. J Neurochem. 2001;79:278-285.
27. Liddell MB, Bayer AJ, Owen MJ. No evidence that common allelic variation in the amyloid precursor protein (APP) gene confers susceptibility to Alzheimer's disease. Hum Mol Genet. 1995;4:853-858.
28. Theuns J, Van Broeckhoven C. Transcriptional regulation of Alzheimer's disease genes: Implications for susceptibility. Hum Mol Genet. 2000;9:2383-2394.
29. Wavrant-De Vrieze F, Crook R, Holmans P, et al. Genetic variability at the amyloid-β precursor protein locus may contribute to the risk of late-onset Alzheimer's disease. Neurosci Lett. 1999;269:67-70.
30. Li L, Perry R, Wu J, et al. Polymorphic tetranucleotide repeat site within intron 7 of the β-amyloid precursor protein gene and its lack of association with Alzheimer's disease. Hum Genet. 1998;103:86-89.
31. Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia in a heterogeneous population: Development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol. 1992;49:453-460.
32. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. BrJ Psychiatry. 1982;140:566-572.
33. Tycko B, Feng L, Nguyen L, et al. Polymorphisms in the human apolipoproteinJ/clusterin gene: Ethnic variation and distribution in Alzheimer's disease. Hum Genet. 1996;98:430-436.
34. Athan ES, Williamson J, Ciappa A, et al. A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. JAMA. 2001;286:2257-2263.
35. Lahiri DK, Song W, Ge YW. Analysis of the 5′-flanking region of the β-amyloid precursor protein gene that contributes to increased promoter activity in differentiated neuronal cells. Molecular Brain Res. 2000;77:185-198.
36. Wingender E, Chen X, Hehl R, et al. TRANSFAC: An integrated system for gene expression regulation. Nucleic Acids Res. 2000;28:316-319.
37. Schug J, Overton GC. TESS: Transcription Elementsearch Software on the WWW: Technical Report CBIL-TR-1997-1001-VO.O of the Computational Biology and Informatics Laboratory. Philadelphia: University of Pennsylvania; 1997.
38. Quitschke WW, Matthews JP, Kraus RJ, Vostrov AA. The initiator element and proximal upstream sequences affect transcriptional activity and start site selection in the amyloid β-protein precursor promoter. J Biol Chem. 1996;271:22231 -22239.
39. Nakagawa T, Kabuto M, Kubota T, et al. Production of amyloid beta protein precursor as a proteinase inhibitor by human astrocytic tumors. Anticancer Res. 1999;19:2963-2968.
40. Carlson CD, Czilli DL, Gitter BD. Regulation of amyloid precursor protein processing by Aβ in human glioma cells. NeurobiolAging. 2000;21:747-756.
41. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997;94:3195-3199.
42. Rauramaa R, Valsanen SB, Luong LA, et al. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:2657-2662.
43. Humphries SE, Luong LA, Ogg MS, et al. The interleukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J. 2001;22:2243-2252.
44. Nakao F, Ihara K, Kusuhara K, et al. Association of IFN-y and IFN regulatory factor 1 polymorphisms with childhood atopic asthma. J Allergy Clin Immunol. 2001;107:499-504.
45. Saito H, Tada S, Ebinuma H, et al. Interferon regulatory factor 1 promoter polymorphism and response to type 1 interferon. J Cell Biochem. 2001;81 (suppl):191-200.
46. van't Hooft FM, von Bahr SJ, Silveira A, et al. Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Arterioscler Thromb Vasc Biol. 1999;19:3063-3070.
47. Bennett ST, Wilson AJ, Esposito L, et al. Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of untransmitted paternal allele: The IMDIAB Group. Nat Genet. 1997;17:350-352.
48. Lambert JC, Berr C, Pasquier F, et al. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Hum Mol Genet. 1998;7:1511-1516.
49. Rebeck GW, Cheung BS, Growdon WB, et al. Lack of independent associations of apolipoprotein E promoter and intron 1 polymorphisms with Alzheimer's disease. Neurosci Lett. 1999;272:155-158.
50. Heijmans BT, Slagboom PE, Gussekloo J, et al. Association of APOE varepsilon2/varepsilon3/varepsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age. Am J Med Genet. 2002;107:201-208.
51. van Duijn CM, Cruts M, Theuns J, et al. Genetic association of the presenilin-1 regulatory region with early-onset Alzheimer's disease in a population-based sample. Eur J Hum Genet. 1999;7:801-806.
52. Theuns J, Del-Favero J, Dermaut B, et al. Genetic variability in the regulatory region of presenilin 1 associated with risk for Alzheimer's disease and variable expression. Hum Mol Genet. 2000;9:325-331.
53. Dermaut B, Roks G, Theuns J, et al. Variable expression of presenilin 1 is not a major determinant of risk for late-onset Alzheimer's disease. J Neurol. 2001;248:935-939.
54. Querfurth HW, Jiang J, Xia W, Selkoe DJ. Enhancer function and novel DNA binding protein activity in the near upstream β APP gene promoter. Gene. 1999;232:125-141.
55. Grilli M, Goffi F, Memo M, Spano P. Interleukin-1β and glutamate activate the NF-κB/Rel binding site from the regulatory region of the amyloid precursor proein gene in primary neuronal cultures. J Biol Chem. 1996;271:15002-15007.
56. Grilli M, Ribola M, Alberici A, et al. Identification and characterization of a κ B/Rel binding site in the regulatory region of the amyloid precursor protein gene. J Biol Chem. 1995;270:26774-26777.